A clinical management algorithm was developed to guide prescribing of QT-prolonging drugs, as every 10 ms increase in the corrected QT interval is associated with a ~5% increased risk of arrhythmias.
Provides a practical algorithm to guide the clinical management of patients at risk for or experiencing drug-induced QT prolongation.
Many drug therapies are associated with prolongation of the QT interval. This may increase the risk of Torsades de Pointes (TdP), a potentially life-threatening cardiac arrhythmia. As the QT interval varies with a change in heart rate, various formulae can adjust for this, producing a 'corrected QT' (QTc) value. Normal QTc intervals are typically 65 years, uncorrected electrolyte disturbances); the potential risk and degree of QT prolongation associated with the proposed drug; and co-prescribed medicines that could increase the risk of QT prolongation. To support clinicians, who are likely to prescribe such medicines in their daily practice, we developed a simple algorithm to help guide clinical management in patients who are at risk of QT prolongation/TdP, those exposed to QT-prolonging medication or have QT prolongation.
Khatib et al. (2020) conducted a review in Drug-induced QT prolongation. Clinical management algorithm was evaluated. A clinical management algorithm was developed to guide prescribing of QT-prolonging drugs, as every 10 ms increase in the corrected QT interval is associated with a ~5% increased risk of arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: